Tempus AI (NASDAQ:TEM) CAO Ryan Bartolucci Sells 6,175 Shares of Stock

Tempus AI, Inc. (NASDAQ:TEM) CAO Ryan Bartolucci sold 6,175 shares of the business’s stock in a transaction that occurred on Tuesday, August 18th. The shares were sold at an average price of $49.61, for a total value of $306,341.75. Following the sale, the chief accounting officer owned 67,866 shares of the company’s stock, valued at approximately $3,366,832.26. This represents a 8.34% decrease in their position. The transaction was disclosed in a filing with the Securities & Exchange Commission, which is available at this link. The sale was made to cover tax withholding obligations related to the vesting of equity awards.

Tempus AI Stock Up 8.8%

Shares of NASDAQ:TEM traded up $5.40 during trading on Thursday, reaching $66.65. 20,103,049 shares of the stock were exchanged, compared to its average volume of 5,600,288. Tempus AI, Inc. has a 1-year low of $40.77 and a 1-year high of $104.32. The stock has a fifty day moving average of $52.44 and a two-hundred day moving average of $51.21. The company has a debt-to-equity ratio of 3.06, a current ratio of 3.30 and a quick ratio of 3.16. The firm has a market cap of $12.03 billion, a price-to-earnings ratio of -46.28 and a beta of 3.58.

Tempus AI (NASDAQ:TEM) last posted its quarterly earnings results on Thursday, July 30th. The company reported ($0.04) earnings per share (EPS) for the quarter, beating the consensus estimate of ($0.14) by $0.10. The business had revenue of $382.49 million during the quarter, compared to the consensus estimate of $379.69 million. Tempus AI had a negative net margin of 17.77% and a negative return on equity of 50.28%. Tempus AI’s revenue was up 21.6% compared to the same quarter last year. During the same quarter last year, the firm posted ($0.22) EPS. Research analysts anticipate that Tempus AI, Inc. will post -1.38 earnings per share for the current fiscal year.

Trending Headlines about Tempus AI

Here are the key news stories impacting Tempus AI this week:

• Positive Sentiment: BTIG raised its price target to $80 from $70 and maintained a “Buy” rating, implying roughly 20% upside from the referenced price. The upgrade provided a direct catalyst for investor buying. BTIG raises Tempus AI price target
• Positive Sentiment: Investor attention is focusing on Tempus AI’s approximately $1.5 billion stock-based agreement to acquire Personalis. The deal is increasingly viewed as strategically valuable because Personalis’ genomic data and cancer-testing capabilities could strengthen Tempus’ precision-medicine and drug-development platform. Tempus AI biotech deal attracts investor attention
• Positive Sentiment: Moderna’s reported cancer-vaccine progress, alongside developments involving Merck, has encouraged investors to believe Tempus’ Personalis acquisition could benefit from increased demand for genomic data and personalized cancer treatment. The connection is indirect, but it has improved sentiment around Tempus’ strategic positioning. Tempus AI stock rises after Merck-Moderna cancer vaccine breakthrough
• Positive Sentiment: The rally was accompanied by unusually high options activity, with investors buying 40,671 call contracts—about 57% above average daily call volume—signaling increased bullish speculation and potentially reinforcing upward momentum.
• Neutral Sentiment: Technical factors also contributed: TEM moved above key moving averages, while coverage characterized the move as a possible short squeeze. These conditions can accelerate gains but may also increase volatility. Tempus AI stock technical rally

Institutional Investors Weigh In On Tempus AI

Institutional investors and hedge funds have recently bought and sold shares of the stock. Vanguard Group Inc. lifted its stake in Tempus AI by 8.7% during the 4th quarter. Vanguard Group Inc. now owns 10,258,621 shares of the company’s stock valued at $605,772,000 after acquiring an additional 817,014 shares in the last quarter. ARK Investment Management LLC grew its stake in shares of Tempus AI by 5.3% in the 4th quarter. ARK Investment Management LLC now owns 7,557,583 shares of the company’s stock worth $446,275,000 after acquiring an additional 381,816 shares in the last quarter. GC Wealth Management RIA LLC bought a new stake in shares of Tempus AI in the 4th quarter worth $399,267,000. Sumitomo Mitsui Trust Group Inc. raised its holdings in shares of Tempus AI by 23.4% in the first quarter. Sumitomo Mitsui Trust Group Inc. now owns 4,326,313 shares of the company’s stock valued at $195,636,000 after purchasing an additional 821,490 shares during the last quarter. Finally, Amova Asset Management Americas Inc. raised its holdings in shares of Tempus AI by 23.4% in the first quarter. Amova Asset Management Americas Inc. now owns 4,326,313 shares of the company’s stock valued at $195,549,000 after purchasing an additional 821,490 shares during the last quarter. 24.22% of the stock is owned by hedge funds and other institutional investors.

Analyst Upgrades and Downgrades

A number of research analysts have recently issued reports on TEM shares. BTIG Research lifted their price objective on shares of Tempus AI from $70.00 to $80.00 and gave the company a “buy” rating in a report on Thursday. Freedom Capital upgraded shares of Tempus AI to a “hold” rating in a report on Tuesday, June 30th. Needham & Company LLC reaffirmed a “buy” rating and issued a $75.00 price target on shares of Tempus AI in a research report on Friday, July 31st. TD Cowen reiterated a “buy” rating on shares of Tempus AI in a research note on Wednesday, July 15th. Finally, Piper Sandler decreased their price objective on Tempus AI from $58.00 to $56.00 and set a “neutral” rating for the company in a report on Tuesday, August 4th. Nine research analysts have rated the stock with a Buy rating, six have issued a Hold rating and two have assigned a Sell rating to the stock. Based on data from MarketBeat.com, the company has a consensus rating of “Hold” and a consensus target price of $65.69.

About Tempus AI

Tempus is a technology-driven healthcare company that applies artificial intelligence and machine learning to clinical and molecular data in order to advance precision medicine. Its primary focus lies in oncology, where the company offers comprehensive genomic profiling, digital pathology services and data-driven insights to inform personalized cancer care. By integrating DNA and RNA sequencing with structured clinical information, Tempus enables clinicians and researchers to identify targeted treatment options for patients based on the genetic characteristics of their tumors.

The company’s core offering centers on a scalable, cloud-based analytics platform that aggregates vast amounts of molecular and clinical data.